PARK
MCID: PRK057
MIFTS: 76

Parkinson Disease, Late-Onset (PARK)

Categories: Genetic diseases, Mental diseases, Metabolic diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Parkinson Disease, Late-Onset

MalaCards integrated aliases for Parkinson Disease, Late-Onset:

Name: Parkinson Disease, Late-Onset 57 29 6 38 73
Parkinson Disease 57 12 24 53 25 75 37 29 55 6 44 40 73
Parkinson's Disease 38 12 76 53 25 54 43 15
Primary Parkinsonism 53 25 75
Paralysis Agitans 12 53 75
Pd 57 25 75
Parkinson Disease, Late-Onset, Susceptibility to 57 13
Late Onset Parkinson's Disease 12 15
Late Onset Parkinson Disease 12 75
Park 57 75
Parkinson Disease, Age of Onset, Modifier 57
Susceptibility to Parkinson's Disease 6
Parkinson Disease, Susceptibility to 57
Idiopathic Parkinson Disease 75
Lewy Body Parkinson Disease 75
Shaking Palsy 53
Parkinson's 63

Characteristics:

OMIM:

57
Inheritance:
isolated cases
multifactorial

Miscellaneous:
progressive disorder
insidious onset
onset mid to late adulthood
levodopa-responsive


HPO:

32
parkinson disease, late-onset:
Onset and clinical course insidious onset progressive
Inheritance sporadic


Classifications:



Summaries for Parkinson Disease, Late-Onset

NIH Rare Diseases : 53 Parkinson disease (PD) is a neurologic disease that affects the movement. The four main symptoms are tremors of the hands, arms, legs, jaw, or head, specially at rest; rigidity, or stiffness; bradykinesia, or slow movement; and postural instability or inability to find balance. The symptoms start slowly, but progress over time, impairing  everyday activities such as walking, talking, or completing simple tasks. Other symptoms may include emotional problems, trouble swallowing and speaking; urinary problems or constipation; skin problems; sleep problems, low blood pressure when standing up from sitting or lying down (postural hypotension), and inexpressive face. Some people will loose their mental abilities (dementia).   Parkinson disease affects several regions of the brain, especially a region known as "substantia nigra" that helps controlling balance and movement. Most cases of PD are sporadic (with no family history), and with onset around 60 years of age; onset before age 20 years is considered to be juvenile-onset Parkinson disease, and after age 50 years is considered late-onset Parkinson disease. However, in some families, there are several cases of Parkinson disease. Familial cases of Parkinson disease, and maybe some sporadic cases, can be caused by changes (mutations) in several genes, such as: Mutations in the SNCA (PARK1), LRRK2 (PARK8), and VPS35 (PARK17) genes are inherited in an autosomal dominant manner. Mutations in genes PARK2, PARK7, and PINK1 (PARK6) appear to be inherited in a recessive manner. Very rare mutations in the TAF1 gene cause Parkinson disease with X-linked inheritance. Mutations in some genes, including GBA and UCHL1 (PARK 5), do not seem to cause Parkinson disease, but to increase the risk of developing the disease in some families. Autosomal recessive PD have earlier onset than autosomal dominant PD. Some studies suggest that these genes are also involved in early-onset or juvenile PD. However, inheriting a mutation does not always mean that a person will have Parkinson's disease, because there may be other genes and environmental factors determining who will develop Parkinson disease. Treatment is usually based on a medication known as levodopa. Other medication includes bromocriptine, pramipexole, ropinirole, amantadine, rasagiline and safinamide.  Deep brain stimulation (DBS) a surgical procedure where electrodes are implanted into the brain may be useful for some people.Prognosis varies, and while some people become disabled, others will have only minor movement problems. Studies have shown that people with PD who have cognitive impairment, postural hypotension, and sleep problems may have a more rapid progression of the disease.

MalaCards based summary : Parkinson Disease, Late-Onset, also known as parkinson disease, is related to parkinson disease 2, autosomal recessive juvenile and parkinson disease 3, autosomal dominant, and has symptoms including seizures, tremor and constipation. An important gene associated with Parkinson Disease, Late-Onset is GBA (Glucosylceramidase Beta), and among its related pathways/superpathways are Parkinson disease and Parkinsons Disease Pathway. Affiliated tissues include Brain and Brain, and related phenotypes are depressivity and dysarthria

Disease Ontology : 12 A synucleinopathy that has material basis in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.

Genetics Home Reference : 25 Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.

OMIM : 57 Parkinson disease was first described by James Parkinson in 1817. It is the second most common neurodegenerative disorder after Alzheimer disease (AD; 104300), affecting approximately 1% of the population over age 50 (Polymeropoulos et al., 1996). (168600)

MedlinePlus : 43 Parkinson's disease (PD) is a type of movement disorder. It happens when nerve cells in the brain don't produce enough of a brain chemical called dopamine. Sometimes it is genetic, but most cases do not seem to run in families. Exposure to chemicals in the environment might play a role. Symptoms begin gradually, often on one side of the body. Later they affect both sides. They include Trembling of hands, arms, legs, jaw and face Stiffness of the arms, legs and trunk Slowness of movement Poor balance and coordination As symptoms get worse, people with the disease may have trouble walking, talking, or doing simple tasks. They may also have problems such as depression, sleep problems, or trouble chewing, swallowing, or speaking. There is no lab test for PD, so it can be difficult to diagnose. Doctors use a medical history and a neurological examination to diagnose it. PD usually begins around age 60, but it can start earlier. It is more common in men than in women. There is no cure for PD. A variety of medicines sometimes help symptoms dramatically. Surgery and deep brain stimulation (DBS) can help severe cases. With DBS, electrodes are surgically implanted in the brain. They send electrical pulses to stimulate the parts of the brain that control movement. NIH: National Institute of Neurological Disorders and Stroke

NINDS : 54 Parkinson's disease (PD) belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells. The four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination. As these symptoms become more pronounced, patients may have difficulty walking, talking, or completing other simple tasks. PD usually affects people over the age of 60.  Early symptoms of PD are subtle and occur gradually.  In some people the disease progresses more quickly than in others.  As the disease progresses, the shaking, or tremor, which affects the majority of people with PD may begin to interfere with daily activities.  Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions.  There are currently no blood or laboratory tests that have been proven to help in diagnosing sporadic PD.  Therefore the diagnosis is based on medical history and a neurological examination.  The disease can be difficult to diagnose accurately.   Doctors may sometimes request brain scans or laboratory tests in order to rule out other diseases.

UniProtKB/Swiss-Prot : 75 Parkinson disease: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

PubMed Health : 63 About parkinson's: Parkinson's is a disease of the nervous system that mostly affects older people. It typically begins after the age of 50. The disease can be very hard to live with because it severely restricts mobility and as a result makes daily activities increasingly difficult. Parkinson's is a progressive disease, which means that in most cases it will continue to gradually get worse. Many people who develop Parkinson’s will require nursing care. There is no cure for the disease and its exact cause is not known, but there are effective treatments that can relieve the symptoms.

Wikipedia : 76 Parkinson''s disease (PD) is a long-term degenerative disorder of the central nervous system that mainly... more...

GeneReviews: NBK1223

Related Diseases for Parkinson Disease, Late-Onset

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 1, Autosomal Dominant Parkinson Disease 15, Autosomal Recessive Early-Onset
Parkinson Disease 12 Parkinson Disease 2, Autosomal Recessive Juvenile
Parkinson Disease 3, Autosomal Dominant Parkinson Disease 4, Autosomal Dominant
Parkinson Disease 6, Autosomal Recessive Early-Onset Parkinson Disease 7, Autosomal Recessive Early-Onset
Parkinson Disease 10 Parkinson Disease 8, Autosomal Dominant
Parkinson Disease 11, Autosomal Dominant Parkinson Disease 13, Autosomal Dominant
Parkinson Disease 14, Autosomal Recessive Parkinson Disease 16
Parkinson Disease 5, Autosomal Dominant Parkinson Disease 17
Parkinson Disease 18, Autosomal Dominant Parkinson Disease 19a, Juvenile-Onset
Parkinson Disease 20, Early-Onset Parkinson Disease 21
Parkinson Disease 22, Autosomal Dominant Parkinson Disease 23, Autosomal Recessive Early-Onset
Juvenile-Onset Parkinson's Disease Early-Onset Parkinson's Disease
Lrrk2-Related Parkinson Disease Vps35-Related Parkinson Disease
Parkinson Disease Type 9 Hereditary Late-Onset Parkinson Disease

Diseases related to Parkinson Disease, Late-Onset via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 518)
# Related Disease Score Top Affiliating Genes
1 parkinson disease 2, autosomal recessive juvenile 34.6 VPS13C PRKN LRRK2
2 parkinson disease 3, autosomal dominant 34.4 PRKN MAPT LRRK2
3 postencephalitic parkinson disease 34.0 MAPT LRRK2
4 parkinson disease 10 33.9 PRKN LRRK2
5 hereditary late-onset parkinson disease 33.8 LRRK2 GBA
6 synucleinopathy 32.5 PRKN MAPT LRRK2 GBA
7 corticobasal degeneration 32.5 MAPT LRRK2 GBA
8 multiple system atrophy 1 32.5 PRKN MAPT LRRK2
9 dementia, lewy body 32.0 PRKN MAPT LRRK2 GBA
10 tremor 30.8 PRKN MAPT LRRK2 GBA ATXN2
11 dementia 30.7 PRKN MAPT LRRK2 GBA ATXN2
12 movement disease 30.7 PRKN MAPT LRRK2 GBA
13 early-onset parkinson's disease 30.4 VPS13C PRKN LRRK2 GBA
14 supranuclear palsy, progressive, 1 30.3 PRKN MAPT LRRK2
15 parkes weber syndrome 12.7
16 parkinson disease 6, autosomal recessive early-onset 12.6
17 parkinson disease 4, autosomal dominant 12.5
18 parkinson disease 15, autosomal recessive early-onset 12.5
19 parkinson disease 23, autosomal recessive early-onset 12.5
20 parkinson disease 1, autosomal dominant 12.5
21 parkinson disease 5, autosomal dominant 12.4
22 parkinson disease 14, autosomal recessive 12.4
23 parkinson disease 8, autosomal dominant 12.4
24 parkinson disease 11, autosomal dominant 12.4
25 parkinson disease 7, autosomal recessive early-onset 12.4
26 parkinson disease 13, autosomal dominant 12.4
27 parkinson disease 22, autosomal dominant 12.3
28 parkinson disease 12 12.2
29 lrrk2-related parkinson disease 12.2
30 pink1 type of young-onset parkinson disease 12.1
31 parkin type of early-onset parkinson disease 12.1
32 vps35-related parkinson disease 12.1
33 parkinson disease 16 12.1
34 parkinson disease, mitochondrial 12.1
35 glaucoma-related pigment dispersion syndrome 11.7
36 prolidase deficiency 11.7
37 pendred syndrome 11.6
38 klippel-trenaunay-weber syndrome 11.3
39 waisman syndrome 11.3
40 personality disorder 11.3
41 carney complex, type 1 11.2
42 lyme disease 11.2
43 polyarteritis nodosa, childhood-onset 11.2
44 arts syndrome 11.2
45 ehlers-danlos syndrome, spondylodysplastic type, 1 11.2
46 spondylodysplastic ehlers-danlos syndrome 11.2
47 cervical dystonia 11.1
48 swallowing disorders 11.1
49 paralysis agitans, juvenile, of hunt 11.1
50 parkinson disease type 9 11.1

Comorbidity relations with Parkinson Disease, Late-Onset via Phenotypic Disease Network (PDN): (show top 50) (show all 53)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Alzheimer Disease
Anxiety Atypical Depressive Disorder
Autonomic Nervous System Disease Bipolar Disorder
Blepharitis Bronchitis
Bronchopneumonia Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Chronic Myocardial Ischemia Communicating Hydrocephalus
Conjunctivitis Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dysthymic Disorder Early-Onset Generalized Limb-Onset Dystonia
Encephalopathy Erythematosquamous Dermatosis
Esophagitis Fecal Incontinence
Generalized Atherosclerosis Heart Disease
Hypothyroidism Intestinal Volvulus
Iron Deficiency Anemia Leukodystrophy
Major Affective Disorder 9 Major Depressive Disorder
Marasmus Mood Disorder
Neurogenic Bladder Obstructive Hydrocephalus
Osteoporosis Paralytic Ileus
Paranoid Schizophrenia Pernicious Anemia
Personality Disorder Prostatic Hypertrophy
Protein-Energy Malnutrition Pseudobulbar Palsy
Schizophrenia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Parkinson Disease, Late-Onset:



Diseases related to Parkinson Disease, Late-Onset

Symptoms & Phenotypes for Parkinson Disease, Late-Onset

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
dysarthria
dystonia
rigidity
bradykinesia
shuffling gait
more
Genitourinary Bladder:
urinary urgency

Head And Neck Face:
masked facies

Abdomen Gastrointestinal:
dysphagia
constipation

Neurologic Behavioral Psychiatric Manifestations:
depression

Head And Neck Nose:
decreased sense of smell


Clinical features from OMIM:

168600

Human phenotypes related to Parkinson Disease, Late-Onset:

32 (show all 24)
# Description HPO Frequency HPO Source Accession
1 depressivity 32 HP:0000716
2 dysarthria 32 HP:0001260
3 tremor 32 HP:0001337
4 dysphagia 32 HP:0002015
5 constipation 32 HP:0002019
6 sleep disturbance 32 HP:0002360
7 hallucinations 32 occasional (7.5%) HP:0000738
8 dystonia 32 HP:0001332
9 mask-like facies 32 HP:0000298
10 rigidity 32 HP:0002063
11 dementia 32 HP:0000726
12 weak voice 32 HP:0001621
13 bradykinesia 32 HP:0002067
14 urinary urgency 32 HP:0000012
15 parkinsonism 32 HP:0001300
16 personality changes 32 HP:0000751
17 postural instability 32 HP:0002172
18 substantia nigra gliosis 32 HP:0011960
19 lewy bodies 32 HP:0100315
20 neuronal loss in central nervous system 32 HP:0002529
21 resting tremor 32 HP:0002322
22 abnormal autonomic nervous system physiology 32 occasional (7.5%) HP:0012332
23 short stepped shuffling gait 32 HP:0007311
24 micrographia 32 HP:0031908

UMLS symptoms related to Parkinson Disease, Late-Onset:


seizures, tremor, constipation, angina pectoris, myoclonus, back pain, pain, headache, bradykinesia, hyposmia, syncope, resting tremor, chronic pain, sciatica, sleep disturbances, muscle rigidity, vertigo/dizziness, equilibration disorder, sleeplessness, urgency of micturition

Drugs & Therapeutics for Parkinson Disease, Late-Onset

PubMedHealth treatment related to Parkinson Disease, Late-Onset: 63

Parkinson's is usually treated with medication. At the beginning of the disease – when the symptoms are not problematic – treatment is sometimes not necessary. If the symptoms get worse, medication can help. Treatment with medication generally aims to replace the lacking dopamine. That often relieves symptoms, but does not slow the progress of the disease. Because over time the drugs are no longer effective, the type and dose of medication has to be adjusted again and again. One option is to use a medication pump. It provides the drug either under the skin or directly into the small intestine and ensures a constant supply.Occupational therapy is used to practice everyday movements and activities. Restricted movement means that the muscles lose strength. Movement exercises (physiotherapy) and sports aim to help counteract that and improve movement and coordination. Speech therapy can be an option if the voice becomes quieter and speech less clear.Deep brain stimulation is recommended to some people whose symptoms are not relieved enough by taking medication. That involves surgery to implant electrodes in certain parts of the brain. They continuously emit electrical impulses that influence muscle activity.

Search Clinical Trials , NIH Clinical Center for Parkinson Disease, Late-Onset

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Parkinson Disease, Late-Onset cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: parkinson disease

Genetic Tests for Parkinson Disease, Late-Onset

Genetic tests related to Parkinson Disease, Late-Onset:

# Genetic test Affiliating Genes
1 Parkinson Disease 29
2 Parkinson Disease, Late-Onset 29 ADH1C ATXN2 GBA GLUD2 MAPT NR4A2 SNCAIP TBP

Anatomical Context for Parkinson Disease, Late-Onset

MalaCards organs/tissues related to Parkinson Disease, Late-Onset:

41
Brain, Subthalamic Nucleus, Testes, Skin, Cortex, Bone, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Parkinson Disease, Late-Onset:
# Tissue Anatomical CompartmentCell Relevance
1 Brain Substantia Nigra pars Compacta Adult Dopaminergic Neurons Affected by disease, potential therapeutic candidate
2 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Parkinson Disease, Late-Onset

Articles related to Parkinson Disease, Late-Onset:

(show top 50) (show all 1783)
# Title Authors Year
1
Determinants of Dual-Task Training Effect Size in Parkinson Disease: Who Will Benefit Most? ( 30531381 )
2019
2
A High-Intensity Exercise Boot Camp for Persons With Parkinson Disease: A Phase II, Pragmatic, Randomized Clinical Trial of Feasibility, Safety, Signal of Efficacy, and Disease Mechanisms. ( 30531382 )
2019
3
Exercise and Parkinson Disease: Comparing Tango, Treadmill, and Stretching. ( 30531383 )
2019
4
Predicting Motor Sequence Learning in People With Parkinson Disease. ( 30531384 )
2019
5
Factors Associated With Responsiveness to Gait and Balance Training in People With Parkinson Disease. ( 30531385 )
2019
6
Auditory Cueing for Gait Impairment in Persons With Parkinson Disease: A Pilot Study of Changes in Response With Disease Progression. ( 30531386 )
2019
7
Lower Extremity Muscle Strength and Force Variability in Persons With Parkinson Disease. ( 30531387 )
2019
8
Eruptive melanocytic nevi in a patient with Parkinson disease treated by carbidopa-levodopa. ( 30555879 )
2019
9
Letter: Deep Brain Stimulation of the Pedunculopontine Nucleus Area in Parkinson Disease: Magnetic Resonance Imaging-Based Anatomoclinical Correlations and Optimal Target. ( 30395324 )
2019
10
Effects of kinesiotherapy on muscle strengthening in patients with Parkinson disease. ( 30444088 )
2019
11
In Reply: Deep Brain Stimulation of the Pedunculopontine Nucleus Area in Parkinson Disease: Magnetic Resonance Imaging-Based Anatomoclinical Correlations and Optimal Target. ( 30445622 )
2019
12
Association analysis of EIF4G1 and Parkinson disease in Xinjiang Uygur and Han nationality. ( 29718834 )
2018
13
Teaching Video NeuroImages: Oculogyric crisis in treated Parkinson disease. ( 29335315 )
2018
14
Central or peripheral autonomic dysfunction in Parkinson disease: Does it matter? ( 29728530 )
2018
15
Improvement During Inpatient Rehabilitation Among Older Adults with Guillain-BarrAc Syndrome, Multiple Sclerosis, Parkinson Disease, and Stroke. ( 29952780 )
2018
16
Prelemniscal Lesion for Selective Improvement of Parkinson Disease Tremor. ( 29408817 )
2018
17
Microstructural changes in patients with Parkinson disease and REM sleep behavior disorder: depressive symptoms versus non-depressed. ( 29442234 )
2018
18
Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants. ( 29361389 )
2018
19
Characteristic Motor and Nonmotor Symptoms Related to Quality of Life in Drug-NaA^ve Patients with Late-Onset Parkinson Disease. ( 29324447 )
2018
20
Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease. ( 29959266 )
2018
21
Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. ( 29855563 )
2018
22
Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease. ( 29567423 )
2018
23
Lewy Body Disease: Clinical and Pathological "Overlap Syndrome" Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). ( 29629495 )
2018
24
Utility of Autonomic Function Tests to Differentiate Dementia with Lewy Bodies and Parkinson Disease with Dementia from Alzheimer Disease. ( 29131019 )
2018
25
Diagnostic Overshadowing of Anxiety in Parkinson Disease: Psychosocial Factors and a Cognitive-Behavioral Model. ( 30239462 )
2018
26
Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study. ( 30382389 )
2018
27
Type I Gaucher disease with bullous pemphigoid and Parkinson disease: A case report. ( 29595653 )
2018
28
Deep Brain Stimulation Surgery for Parkinson Disease Coexisting With Communicating Hydrocephalus: A Case Report. ( 30532732 )
2018
29
Parkinson disease with constipation: clinical features and relevant factors. ( 29330419 )
2018
30
Parkinson disease: LRRK2 variants linked to PD and Crohn's disease. ( 29391585 )
2018
31
Apolipoprotein E Polymorphisms and Parkinson Disease With or Without Dementia: A Meta-Analysis Including 6453 Participants. ( 30526202 )
2018
32
Disrupted network topology in patients with Lewy bodies dementia compared to Alzheimer's disease, Parkinson disease dementia and Health Control. ( 30440768 )
2018
33
Challenges in Defining Inappropriate Medication Use in Parkinson Disease Dementia. ( 30285044 )
2018
34
Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease. ( 30285047 )
2018
35
The Effectiveness of Reality Orientation Therapy in the Treatment of Parkinson Disease Dementia. ( 30286613 )
2018
36
Erratum: A practical approach to detection and treatment of depression in Parkinson disease and dementia. ( 30140576 )
2018
37
Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease. ( 30057156 )
2018
38
Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. ( 30146185 )
2018
39
Dysphagia Causes Symptom Fluctuations after Oral L-DOPA Treatment in a Patient with Parkinson Disease. ( 29681829 )
2018
40
Prevalence and clinical correlation of dysphagia in Parkinson disease: a study on Chinese patients. ( 28699630 )
2018
41
Critical Dysphagia is Common in Parkinson Disease and Occurs Even in Early Stages: A Prospective Cohort Study. ( 28828545 )
2018
42
NMDAR encephalitis presenting as akinesia in a patient with Parkinson disease. ( 30557688 )
2018
43
White matter differences between essential tremor and Parkinson disease. ( 30504432 )
2018
44
The overlap between Essential tremor and Parkinson disease. ( 28729090 )
2018
45
Frozen shoulder or shoulder stiffness from Parkinson disease? ( 30276531 )
2018
46
Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. ( 29710331 )
2018
47
Response to Letter "Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke: Methodologic Issues". ( 30053989 )
2018
48
Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke: Methodologic Issues. ( 30053990 )
2018
49
Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review. ( 30118919 )
2018
50
Heart rate variability in Parkinson disease and idiopathic REM sleep behavior disorder. ( 30128681 )
2018

Variations for Parkinson Disease, Late-Onset

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease, Late-Onset:

75
# Symbol AA change Variation ID SNP ID
1 PRKN p.Cys253Tyr VAR_019749 rs747427602
2 PRKN p.Arg256Cys VAR_019750 rs150562946
3 PRKN p.Arg275Trp VAR_019752 rs34424986
4 PRKN p.Asp280Asn VAR_019753 rs72480422

ClinVar genetic disease variations for Parkinson Disease, Late-Onset:

6 (show top 50) (show all 87)
# Gene Variation Type Significance SNP ID Assembly Location
1 ATXN3 NM_004993.5(ATXN3): c.892_894CAG(8_36) (p.Gln298_Gln305=) NT expansion Pathogenic,risk factor rs193922928 GRCh37 Chromosome 14, 92537355: 92537357
2 ATXN3 NM_004993.5(ATXN3): c.892_894CAG(8_36) (p.Gln298_Gln305=) NT expansion Pathogenic,risk factor rs193922928 GRCh38 Chromosome 14, 92071011: 92071013
3 GBA NM_000157.3(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant risk factor rs421016 GRCh37 Chromosome 1, 155205043: 155205043
4 GBA NM_000157.3(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant risk factor rs421016 GRCh38 Chromosome 1, 155235252: 155235252
5 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant risk factor rs76763715 GRCh37 Chromosome 1, 155205634: 155205634
6 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant risk factor rs76763715 GRCh38 Chromosome 1, 155235843: 155235843
7 GBA NM_000157.3(GBA): c.1504C> T (p.Arg502Cys) single nucleotide variant Pathogenic rs80356771 GRCh37 Chromosome 1, 155204987: 155204987
8 GBA NM_000157.3(GBA): c.1504C> T (p.Arg502Cys) single nucleotide variant Pathogenic rs80356771 GRCh38 Chromosome 1, 155235196: 155235196
9 GBA NM_001005741.2(GBA): c.1444G> A (p.Asp482Asn) single nucleotide variant risk factor rs75671029 GRCh37 Chromosome 1, 155205047: 155205047
10 GBA NM_001005741.2(GBA): c.1444G> A (p.Asp482Asn) single nucleotide variant risk factor rs75671029 GRCh38 Chromosome 1, 155235256: 155235256
11 FGF20 NM_019851.2(FGF20): c.*182C> T single nucleotide variant Uncertain significance rs12720208 GRCh38 Chromosome 8, 16992890: 16992890
12 FGF20 NM_019851.2(FGF20): c.*182C> T single nucleotide variant Uncertain significance rs12720208 GRCh37 Chromosome 8, 16850399: 16850399
13 SNCAIP NM_005460.3(SNCAIP): c.1861C> T (p.Arg621Cys) single nucleotide variant Likely benign rs28937592 GRCh37 Chromosome 5, 121786403: 121786403
14 SNCAIP NM_005460.3(SNCAIP): c.1861C> T (p.Arg621Cys) single nucleotide variant Likely benign rs28937592 GRCh38 Chromosome 5, 122450708: 122450708
15 NR4A2 NR4A2, 1-BP DEL, -291T deletion Uncertain significance
16 NR4A2 NR4A2, -245T-G single nucleotide variant Uncertain significance
17 MT-ND1 m.3397A> G single nucleotide variant Pathogenic rs199476120 GRCh37 Chromosome MT, 3397: 3397
18 MT-ND1 m.3397A> G single nucleotide variant Pathogenic rs199476120 GRCh38 Chromosome MT, 3397: 3397
19 GLUD2 NM_012084.3(GLUD2): c.1492T> G (p.Ser498Ala) single nucleotide variant Pathogenic rs9697983 GRCh37 Chromosome X, 120183030: 120183030
20 GLUD2 NM_012084.3(GLUD2): c.1492T> G (p.Ser498Ala) single nucleotide variant Pathogenic rs9697983 GRCh38 Chromosome X, 121049176: 121049176
21 DNAJC13 NM_015268.3(DNAJC13): c.2564A> G (p.Asn855Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs387907571 GRCh37 Chromosome 3, 132196839: 132196839
22 DNAJC13 NM_015268.3(DNAJC13): c.2564A> G (p.Asn855Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs387907571 GRCh38 Chromosome 3, 132477995: 132477995
23 ATXN2 NM_002973.3: c.496_498CAG([33_?]) NT expansion Pathogenic,risk factor
24 TNK2 NM_005781.4(TNK2): c.1912G> A (p.Val638Met) single nucleotide variant Uncertain significance rs201407161 GRCh37 Chromosome 3, 195595212: 195595212
25 TNK2 NM_005781.4(TNK2): c.1912G> A (p.Val638Met) single nucleotide variant Uncertain significance rs201407161 GRCh38 Chromosome 3, 195868341: 195868341
26 GBA NM_000157.3(GBA): c.1223C> T (p.Thr408Met) single nucleotide variant Conflicting interpretations of pathogenicity rs75548401 GRCh37 Chromosome 1, 155206037: 155206037
27 GBA NM_000157.3(GBA): c.1223C> T (p.Thr408Met) single nucleotide variant Conflicting interpretations of pathogenicity rs75548401 GRCh38 Chromosome 1, 155236246: 155236246
28 PARK7 NM_007262.4(PARK7): c.399G> C (p.Met133Ile) single nucleotide variant Uncertain significance rs398124657 GRCh37 Chromosome 1, 8037788: 8037788
29 PARK7 NM_007262.4(PARK7): c.399G> C (p.Met133Ile) single nucleotide variant Uncertain significance rs398124657 GRCh38 Chromosome 1, 7977728: 7977728
30 VPS35 NM_018206.5(VPS35): c.1576C> T (p.Arg526Cys) single nucleotide variant Uncertain significance rs398124658 GRCh37 Chromosome 16, 46702913: 46702913
31 VPS35 NM_018206.5(VPS35): c.1576C> T (p.Arg526Cys) single nucleotide variant Uncertain significance rs398124658 GRCh38 Chromosome 16, 46669001: 46669001
32 PINK1 NM_032409.2(PINK1): c.644C> T (p.Pro215Leu) single nucleotide variant Uncertain significance rs371854396 GRCh37 Chromosome 1, 20964591: 20964591
33 PINK1 NM_032409.2(PINK1): c.644C> T (p.Pro215Leu) single nucleotide variant Uncertain significance rs371854396 GRCh38 Chromosome 1, 20638098: 20638098
34 PINK1 NM_032409.2(PINK1): c.923T> A (p.Leu308Gln) single nucleotide variant Uncertain significance rs398124659 GRCh37 Chromosome 1, 20971129: 20971129
35 PINK1 NM_032409.2(PINK1): c.923T> A (p.Leu308Gln) single nucleotide variant Uncertain significance rs398124659 GRCh38 Chromosome 1, 20644636: 20644636
36 LRRK2 NM_198578.3(LRRK2): c.2352C> A (p.Ser784Arg) single nucleotide variant Uncertain significance rs398124660 GRCh37 Chromosome 12, 40677787: 40677787
37 LRRK2 NM_198578.3(LRRK2): c.2352C> A (p.Ser784Arg) single nucleotide variant Uncertain significance rs398124660 GRCh38 Chromosome 12, 40283985: 40283985
38 LRRK2 NM_198578.3(LRRK2): c.7300A> G (p.Ile2434Val) single nucleotide variant Uncertain significance rs398124661 GRCh37 Chromosome 12, 40758762: 40758762
39 LRRK2 NM_198578.3(LRRK2): c.7300A> G (p.Ile2434Val) single nucleotide variant Uncertain significance rs398124661 GRCh38 Chromosome 12, 40364960: 40364960
40 MAPT NM_016835.4(MAPT): c.1838_1840delATA (p.Asn613del) deletion Pathogenic,risk factor rs63751392 GRCh37 Chromosome 17, 44087740: 44087742
41 MAPT NM_016835.4(MAPT): c.1838_1840delATA (p.Asn613del) deletion Pathogenic,risk factor rs63751392 GRCh38 Chromosome 17, 46010374: 46010376
42 GBA NM_000157.3(GBA): c.1440G> C (p.Lys480Asn) single nucleotide variant Uncertain significance rs1057519356 GRCh37 Chromosome 1, 155205051: 155205051
43 GBA NM_000157.3(GBA): c.1440G> C (p.Lys480Asn) single nucleotide variant Uncertain significance rs1057519356 GRCh38 Chromosome 1, 155235260: 155235260
44 GBA NM_000157.3(GBA): c.1277C> T (p.Pro426Leu) single nucleotide variant Uncertain significance rs1057519357 GRCh37 Chromosome 1, 155205583: 155205583
45 GBA NM_000157.3(GBA): c.1277C> T (p.Pro426Leu) single nucleotide variant Uncertain significance rs1057519357 GRCh38 Chromosome 1, 155235792: 155235792
46 GBA NM_000157.3(GBA): c.221G> C (p.Gly74Ala) single nucleotide variant Uncertain significance rs371592589 GRCh37 Chromosome 1, 155209763: 155209763
47 GBA NM_000157.3(GBA): c.221G> C (p.Gly74Ala) single nucleotide variant Uncertain significance rs371592589 GRCh38 Chromosome 1, 155239972: 155239972
48 GBA NM_000157.3(GBA): c.1220T> C (p.Ile407Thr) single nucleotide variant Uncertain significance rs1057519358 GRCh38 Chromosome 1, 155236249: 155236249
49 GBA NM_000157.3(GBA): c.1220T> C (p.Ile407Thr) single nucleotide variant Uncertain significance rs1057519358 GRCh37 Chromosome 1, 155206040: 155206040
50 PODXL NM_005397.3(PODXL): c.1285C> A (p.Pro429Thr) single nucleotide variant Uncertain significance rs869312170 GRCh37 Chromosome 7, 131190725: 131190725

Copy number variations for Parkinson Disease, Late-Onset from CNVD:

7 (show all 18)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 23691 1 173049146 173078950 Copy number PAPPA2 Parkinson disease
2 27433 1 20832534 20850591 Genomic rearrangemen ts PINK1 Parkinson disease
3 60306 11 84948993 84958207 Copy number DLG2 Parkinson disease
4 115237 17 55581582 55809920 Copy number USP32 Parkinson disease
5 132540 19 59310648 59326954 Genomic rearrangemen ts PRPF31 Parkinson disease
6 170895 3 161200000 193800000 Copy number EIF4G1 Parkinson disease
7 186570 4 36900000 88200000 Duplication or tripl ication SNCA Parkinson disease
8 187375 4 48300000 99100000 Copy number SNCA Parkinson disease
9 189219 4 71528873 71716513 Copy number ENAM Parkinson disease
10 190419 4 88200000 94000000 Triplication SNCA Parkinson disease
11 190793 4 90645250 90759447 Duplication SNCA Parkinson disease
12 190807 4 90865727 90978470 Duplication or tripl ication SNCA Parkinson disease
13 195489 5 151389412 151513092 Copy number GLRA1 Parkinson disease
14 207784 6 161000000 164500000 Gain or loss PARK2 Parkinson disease
15 207856 6 161768590 163148834 Copy number PARK2 Parkinson disease
16 207937 6 162471089 162677104 Copy number PARK2 Parkinson disease
17 211738 6 336751 356443 Deletion IRF4 Parkinson disease
18 237664 8 25038472 25171648 Copy number Parkinson disease

Expression for Parkinson Disease, Late-Onset

Search GEO for disease gene expression data for Parkinson Disease, Late-Onset.

Pathways for Parkinson Disease, Late-Onset

Pathways related to Parkinson Disease, Late-Onset according to KEGG:

37
# Name Kegg Source Accession
1 Parkinson disease hsa05012

Pathways related to Parkinson Disease, Late-Onset according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.85 ATXN2 LRRK2 MIR433 PRKN

GO Terms for Parkinson Disease, Late-Onset

Biological processes related to Parkinson Disease, Late-Onset according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.63 GBA LRRK2 PRKN
2 regulation of autophagy GO:0010506 9.54 LRRK2 MAPT PRKN
3 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.51 LRRK2 PRKN
4 stress granule assembly GO:0034063 9.49 ATXN2 MAPT
5 cellular response to dopamine GO:1903351 9.48 LRRK2 PRKN
6 cellular response to manganese ion GO:0071287 9.43 LRRK2 PRKN
7 intracellular distribution of mitochondria GO:0048312 9.4 LRRK2 MAPT
8 negative regulation of neuron death GO:1901215 9.33 GBA LRRK2 PRKN
9 regulation of mitochondrial fission GO:0090140 9.32 LRRK2 MAPT
10 protein localization to mitochondrion GO:0070585 9.26 LRRK2 PRKN
11 regulation of synaptic vesicle transport GO:1902803 8.96 LRRK2 PRKN
12 mitochondrion organization GO:0007005 8.92 GBA LRRK2 PRKN VPS13C

Molecular functions related to Parkinson Disease, Late-Onset according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tubulin binding GO:0015631 8.8 LRRK2 MAPT PRKN

Sources for Parkinson Disease, Late-Onset

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....